ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
[Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
Stanford Center for Health Education Launches Online Program… 08/11/2020
HTA Whitepaper Discusses Resulting Value and Economic Benefits 04/16/2021
New Podcast Featuring ICER President on Consequences of High… 04/27/2021
What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020